DOHH and glioblastoma: Additionally, an elevated expression of DOHH has been identified as one of the molecular markers that is associated with the poor prognosis of GBM, where proteomic analysis of 84 GBM patients revealed that DOHH was highly expressed in short-term (<6 months) survivors compared with long-term survivors [56].